S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.81 (+1.10%)
MSFT   402.26 (+0.79%)
META   485.86 (+1.00%)
GOOGL   157.26 (+2.06%)
AMZN   177.85 (+1.84%)
TSLA   141.74 (-3.61%)
NVDA   795.05 (+4.34%)
AMD   149.06 (+1.65%)
NIO   4.03 (+6.05%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   110.00 (+3.03%)
GE   151.13 (+2.07%)
CGC   7.96 (+0.38%)
DIS   113.09 (+0.43%)
AMC   3.36 (+6.33%)
PFE   26.43 (+1.65%)
PYPL   63.42 (+1.78%)
XOM   121.45 (+1.31%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.81 (+1.10%)
MSFT   402.26 (+0.79%)
META   485.86 (+1.00%)
GOOGL   157.26 (+2.06%)
AMZN   177.85 (+1.84%)
TSLA   141.74 (-3.61%)
NVDA   795.05 (+4.34%)
AMD   149.06 (+1.65%)
NIO   4.03 (+6.05%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   110.00 (+3.03%)
GE   151.13 (+2.07%)
CGC   7.96 (+0.38%)
DIS   113.09 (+0.43%)
AMC   3.36 (+6.33%)
PFE   26.43 (+1.65%)
PYPL   63.42 (+1.78%)
XOM   121.45 (+1.31%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.81 (+1.10%)
MSFT   402.26 (+0.79%)
META   485.86 (+1.00%)
GOOGL   157.26 (+2.06%)
AMZN   177.85 (+1.84%)
TSLA   141.74 (-3.61%)
NVDA   795.05 (+4.34%)
AMD   149.06 (+1.65%)
NIO   4.03 (+6.05%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   110.00 (+3.03%)
GE   151.13 (+2.07%)
CGC   7.96 (+0.38%)
DIS   113.09 (+0.43%)
AMC   3.36 (+6.33%)
PFE   26.43 (+1.65%)
PYPL   63.42 (+1.78%)
XOM   121.45 (+1.31%)
S&P 500   5,027.65 (+1.22%)
DOW   38,365.48 (+1.00%)
QQQ   420.44 (+1.40%)
AAPL   166.81 (+1.10%)
MSFT   402.26 (+0.79%)
META   485.86 (+1.00%)
GOOGL   157.26 (+2.06%)
AMZN   177.85 (+1.84%)
TSLA   141.74 (-3.61%)
NVDA   795.05 (+4.34%)
AMD   149.06 (+1.65%)
NIO   4.03 (+6.05%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   110.00 (+3.03%)
GE   151.13 (+2.07%)
CGC   7.96 (+0.38%)
DIS   113.09 (+0.43%)
AMC   3.36 (+6.33%)
PFE   26.43 (+1.65%)
PYPL   63.42 (+1.78%)
XOM   121.45 (+1.31%)
NASDAQ:FWBI

First Wave BioPharma (FWBI) Stock Price, News & Analysis

$3.07
+0.47 (+18.08%)
(As of 02:33 PM ET)
Today's Range
$2.42
$3.10
50-Day Range
$2.60
$9.24
52-Week Range
$2.42
$65.00
Volume
42,629 shs
Average Volume
251,912 shs
Market Capitalization
$6.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$118.00

First Wave BioPharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,743.6% Upside
$118.00 Price Target
Short Interest
Healthy
3.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$15,968 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.83 out of 5 stars

FWBI stock logo

About First Wave BioPharma Stock (NASDAQ:FWBI)

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

FWBI Stock Price History

FWBI Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Why Is First Wave BioPharma (FWBI) Stock Up Today?
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
First Wave BioPharma price target set at $40 at Roth MKM
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
See More Headlines
Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
4/22/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FWBI
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$118.00
High Stock Price Target
$200.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+4,527.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-15,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.31 per share

Miscellaneous

Free Float
2,015,000
Market Cap
$5.18 million
Optionable
Not Optionable
Beta
1.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. James R. Sapirstein M.B.A. (Age 63)
    R.Ph., CEO & Chairman
    Comp: $906.2k
  • Ms. Sarah Romano CPA (Age 43)
    Chief Financial Officer
    Comp: $624.88k
  • Dr. Jack A. Syage Ph.D. (Age 69)
    President, COO & Director
  • Ms. Amy Chandler-Skerkis (Age 55)
    Vice President of Regulatory Affairs, QA & Compliance
  • Mr. Martin Krusin M.B.A.
    Senior Vice President of Corporate Development

FWBI Stock Analysis - Frequently Asked Questions

Should I buy or sell First Wave BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FWBI shares.
View FWBI analyst ratings
or view top-rated stocks.

What is First Wave BioPharma's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for First Wave BioPharma's stock. Their FWBI share price targets range from $36.00 to $200.00. On average, they anticipate the company's share price to reach $118.00 in the next twelve months. This suggests a possible upside of 3,743.6% from the stock's current price.
View analysts price targets for FWBI
or view top-rated stocks among Wall Street analysts.

How have FWBI shares performed in 2024?

First Wave BioPharma's stock was trading at $4.20 at the start of the year. Since then, FWBI shares have decreased by 26.9% and is now trading at $3.07.
View the best growth stocks for 2024 here
.

Are investors shorting First Wave BioPharma?

First Wave BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 55,000 shares, an increase of 295.7% from the March 15th total of 13,900 shares. Based on an average daily trading volume, of 140,300 shares, the short-interest ratio is presently 0.4 days. Approximately 3.0% of the company's shares are sold short.
View First Wave BioPharma's Short Interest
.

When is First Wave BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our FWBI earnings forecast
.

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma, Inc. (NASDAQ:FWBI) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($13,734.00) earnings per share for the quarter, missing analysts' consensus estimates of ($3,318.00) by $10,416.00.

When did First Wave BioPharma's stock split?

Shares of First Wave BioPharma reverse split on the morning of Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of First Wave BioPharma?

Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FWBI) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners